Inhibition of RyR2 leak with dantrolene therapy prevents VT/VF and SCD
arrhythmias, VT/VF
ARRHYTHMIAS, CARDIAC HYPERTROPHY, PREMATURE VENTRICULAR CONTRACTIONS
To study the effects of RyR2 leak inhibition on SCD and HF, we leveraged a pressure overload guinea pig model of HF/SCD with spontaneous arrhythmias. Unique to this model is the high incidence of premature ventricular contractions (PVCs) and VT/VF, leading to SCD in about two-thirds of the animals within 4 weeks. Notably, the SCD occurs early on, in the first 2 weeks over the course of cardiac hypertrophy, even before the heart dilates or progresses into failure (